Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01206296 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by Medstar Health Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01206296 is a Phase 2 study that was terminated before completion, run by Medstar Health Research Institute. The registered enrollment target is 9 participants.
The verdict
NCT01206296, a Phase 2 study, was terminated before completion, sponsored by Medstar Health Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a phase II study evaluating the use of intraperitoneal gemcitabine given intraoperatively and as adjuvant therapy for patients with resectable pancreas cancer. The primary objective of this study is to evaluate the overall safety of intraperitoneal gemcitabine given intraoperatively and postoperatively for adjuvant treatment of resectable pancreatic adenocarcinoma. The secondary objectives are to evaluate the efficacy of this treatment regimen as reflected in overall survival at 2-years, to study the patterns of disease recurrence following this treatment, to study the pharmacology of intraperitoneal gemcitabine and to study changes in peritoneal cytology with pancreatic cancer resection.
Interventions
- DRUG Intraperitoneal Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-08 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01206296
The ClinicalTrials.gov registry entry for NCT01206296 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intraperitoneal Gemcitabine is the first listed.
NCT01206296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01206296 about?
NCT01206296 is a clinical study titled "Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma". This is a phase II study evaluating the use of intraperitoneal gemcitabine given intraoperatively and as adjuvant therapy for patients with resectable pancreas cancer. The primary objective of this study is to evaluate the overall safety of intraperitoneal gemcitabine given intraoperatively and pos...
What is the current status of trial NCT01206296?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2010-08. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01206296?
The interventions under investigation include: Intraperitoneal Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT01206296?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.